A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima H.
Madan, Ravi Amrit
Apolo, Andrea Borghese
Parnes, Howard L.
Wright, John Joseph
Trepel, Jane B.
Beatson, Melony A.
Harold, Nancy
Couvillon, Anna
Steinberg, Seth M.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Bethesda, MD 20892 USA
[4] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[5] NCI, Rockville, MD USA
[6] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5095
引用
收藏
页数：1
相关论文
共 50 条
  • [41] An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC)
    MacVicar, G. R.
    Greco, A.
    Reeves, J.
    Maleski, J.
    Holmlund, J.
    Leopold, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] AUSTRALIAN EXPERIENCE WITH CABAZITAXEL IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC)
    Ng, S.
    Gurney, H.
    Parente, P.
    Bahre, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 63 - 63
  • [43] A study of sustained androgen signaling dependence in metastatic castrate resistant prostate cancer (mCRPC)
    Boukovala, M.
    Spetsieris, N.
    Karalis, K.
    Alafis, I.
    Weldon, J. A.
    Karlou, M.
    Tu, S-M.
    Aparicio, A.
    Araujo, J. C.
    Corn, P.
    Subudhi, S. K.
    Zurita-Saavedra, A. J.
    Logothetis, C.
    Efstathiou, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S524 - S524
  • [44] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [46] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [47] A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer
    Mardjuadi, F.
    Medioni, J.
    Kerger, J.
    Canon, J. L.
    Duck, L.
    Oudard, S.
    Clausse, M.
    D'Hondt, L.
    Moxhon, A.
    Machiels, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer
    Jeske, Stephanie
    Tagawa, Scott T.
    Olowokure, Olugbenga
    Selzer, Jodi
    Giannakakou, Paraskevi
    Nanus, David M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) : 676 - 681
  • [49] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [50] Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer
    Vaishampayan, Ulka N.
    Marur, Shanthi
    Heilbrun, Lance K.
    Cher, Michael L.
    Dickow, Brenda
    Smith, Daryn W.
    Al Hasan, Samir A.
    Eliason, James
    JOURNAL OF UROLOGY, 2009, 182 (01): : 317 - 323
12345